Decibel Therapeutics, Inc.
Funding rounds
2 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Nov 2020 | $55 M | No. 2 | $50 to $250 million | equity | SEC | |
| Oct 2015 | $32 M | No. 1 | $10 to $50 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Decibel Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Nov 2020).
SEC Form D · Nov 2020
The industry group it chose in its notices: Biotechnology.
SEC Form D · Nov 2020
That is all the official record says: Decibel Therapeutics, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
Products and services#
No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).
Investors#
22 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| Casdin Partners Master Fund, L.P. | Fund or asset manager | not stated | not stated | Held Series D preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| GSK PLC | Fund or asset manager | not stated | not stated | Held Series A, C and D preferred stock, 10% owner, director (Form 3, 2021) | SEC Form 3 |
| GV 2016 GP, L.L.C. | Other | not stated | not stated | Held Series A preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| GV 2016 GP, L.P. | Fund or asset manager | not stated | not stated | Held Series A preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| GV 2016, L.P. | Fund or asset manager | not stated | not stated | Held Series A preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| GV 2017 GP, L.L.C. | Other | not stated | not stated | Held Series C preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| GV 2017 GP, L.P. | Fund or asset manager | not stated | not stated | Held Series C preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| GV 2017, L.P. | Fund or asset manager | not stated | not stated | Held Series C preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| GV 2019 GP, L.L.C. | Other | not stated | not stated | Held Series D preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| GV 2019 GP, L.P. | Fund or asset manager | not stated | not stated | Held Series D preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| GV 2019, L.P. | Fund or asset manager | not stated | not stated | Held Series D preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| Longevity Fund 2 LP | Fund or asset manager | not stated | not stated | Held Series C preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| Orbimed Advisors LLC | Fund or asset manager | not stated | not stated | Held Series D preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| OrbiMed Capital GP VIII LLC | Fund or asset manager | not stated | not stated | Held Series D preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| Orbimed Capital LLC | Fund or asset manager | not stated | not stated | Held Series D preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| OrbiMed Genesis GP LLC | Other | not stated | not stated | Held Series D preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| Regeneron Pharmaceuticals, Inc. | Fund or asset manager | not stated | not stated | Held Series B and C preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| Schroder Adveq cPl Global Management III L.P. | Fund or asset manager | not stated | not stated | Held Series C preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| Schroder Adveq Management Luxembourg Sarl | Fund or asset manager | not stated | not stated | Held Series C preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| Third Rock Ventures GP III, L.P. | Venture capital | not stated | not stated | Held Series A, C and D preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| Third Rock Ventures III, L.P. | Venture capital | not stated | not stated | Held Series A, C and D preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| TRV GP III, LLC | Other | not stated | not stated | Held Series A, C and D preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 23 investors.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Elisabeth Leiderman | Executive officer | Nov 2020 |
| Laurence Reid | Executive officer | Nov 2020 |
| John J. Keilty | Executive officer | Jan 2017 |
| Steven H. Holtzman | Executive officer | Jan 2017 |
| Kevin Starr | Executive officer | Oct 2015 |
| Michael Solomon | Executive officer | Oct 2015 |
| Anthony A. Philippakis | Director | Nov 2020 |
| Christine A. Poon | Director | Nov 2020 |
| Laurence Reid | Director | Nov 2020 |
| Neil A. Exter | Director | Nov 2020 |
| Peter A. Thompson | Director | Nov 2020 |
| Craig H. Muir | Director | Jan 2017 |
| George H. Scangos | Director | Jan 2017 |
| Jeffrey H. Jonas | Director | Jan 2017 |
| Jens H. Eckstein | Director | Jan 2017 |
| Kevin Starr | Director | Jan 2017 |
| Roger H. Brown | Director | Jan 2017 |
| Steven H. Holtzman | Director | Jan 2017 |
| Troy H. Brennan | Director | Jan 2017 |
| Craig Muir | Director | Oct 2015 |
| Jens Eckstein | Director | Oct 2015 |